Influence of a positive pressure Therapie for sleep apnoea Treatment on stroke volume, cardiac Output, ejection fraction and pre-ejection period during sleep.

Influence of a positive pressure Therapie for sleep apnoea Treatment on stroke volume, cardiac Output, ejection fraction and pre-ejection period during sleep. - PAP-hemodynamics

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022223

Enrollment

Registered

2020-06-19

Start date

2020-06-21

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G47.0 G47.3

Interventions

Group 1: single arm: Inclusion of OSA patients, state of heart and vessels as recorded by Anamnese, 2. If indication for diagnistic polysomnography (PSG) is given (BUB stage 4) this is done together w

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who come for the first time into the sleep laboratory with indication for a diagnostic polysomnographic investigation (Level 4 of the treatment Guidelines) and patients who come for the first time into the sleep laboratory with confirmed OSA diagnosis and indication for immediate sleep apnoea therapy onset.

Exclusion criteria

Exclusion criteria: patients who are unable to give written consent for study recruitment

Design outcomes

Primary

Measure	Time frame
1. To identify patients in which the cardiac performance is reduced with increasing therapy pressure 2. To identify patients in which the cardiac Performance is enhanced with increasing therapy pressure 3. To identify patients in which increasing pressure does not affect hemodynamic parameters at all	—

Secondary

Measure	Time frame
1. To identify patients in which the cardiac performance is reduced with increasing therapy pressure beneath the lower level of the nomal value range 2. To identify patients in which the cardiac Performance is enhanced with increasing therapy pressure and raises from critical hemdonyamic values beneath the lower Level of the normal value range into the normal value range 3. To identify patients in which hemodynamic values are always beneath the lower level of normal value range indepedend from the therapy pressure value	—

Measure

Time frame

1. To identify patients in which the cardiac performance is reduced with increasing therapy pressure beneath the lower level of the nomal value range 2. To identify patients in which the cardiac Performance is enhanced with increasing therapy pressure and raises from critical hemdonyamic values beneath the lower Level of the normal value range into the normal value range 3. To identify patients in which hemodynamic values are always beneath the lower level of normal value range indepedend from the therapy pressure value

—

Countries

Germany

Contacts

Public ContactJens Kerl

Fachkrankenhaus Kloster Grafschaft GmbH

j.kerl@fkkg.de02972-7911703

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026